Wednesday, September 2, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 11, 2026

Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge?

View original at finance.yahoo.com
“For AstraZeneca, the latest twelve month Free Cash Flow (FCF) is about US$9.49b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AstraZeneca's DCF analysis suggests the stock is undervalued by 36.2%

    60% confidence

  • The DCF model arrives at an estimated intrinsic value of US$238.68 per share for AstraZeneca

    60% confidence

  • AstraZeneca has a valuation score of 3 out of 6

    60% confidence

Data points we hold from this source

AstraZeneca AB · stock return 30day5.2 percent
AstraZeneca AB · stock return 1year54.8 percent
AstraZeneca AB · free cash flow9.49 USD
AstraZeneca AB · stock return ytd12.1 percent
AstraZeneca AB · projected free cash flow20.16 USD
AstraZeneca AB · valuation score3 out_of_6
AstraZeneca AB · intrinsic value dcf238.68 USD
AstraZeneca AB · stock return 7day-0.6 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge: Late-August 2026 Funding Wave Spans Fintech, Enterprise Agents, and Robotics
A dense cluster of funding rounds landing on 2026-08-28 — from identity/fraud fintech player Socure ($156M plus its acquisition of Fravity) to enterprise AI agent startups (Instinct, Generalist AI, Owner), model infrastructure (Stability AI, Emerald AI), and autonomous logistics/aerospace (Gatik, Regent Craft) — signals investors are rotating aggressively into AI-native companies with demonstrable ROI, especially in financial risk/compliance and back-office automation. Parallel signals (Multiverse Computing's compression benchmarks cutting inference cost/latency, and Arkestro/CloneOps.ai publishing hard savings and labor-displacement figures) suggest the funding is chasing efficiency and measurable economic impact rather than pure model scale.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,980
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,980 facts checked against source5,267 source documents archived
Query this data → isubstrate.com
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge? — Source | Via News | Via News